UPDATE: Oppenheimer Starts PROLOR Biotech (PBTH) at Outperform; Opportunity in Therapeutic Proteins
Tweet
Share
E-mailGet Alerts PBTH Hot Sheet
Price: $8.23 --0%
Rating Summary:
4 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
4 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
(Updated - August 29, 2012 8:54 AM EDT)
Oppenheimer initiates coverage on PROLOR Biotech (NYSE: PBTH) with a Outperform. PT $7.00.
Analyst, Boris Peaker, said, "PROLOR is a biopharmaceutical company developing proprietary long-acting versions of already approved therapeutics. PROLOR's leading asset is hGH-CTP, a long-acting version of human growth hormone (HGH). A Phase III trial of hGH-CTP in adults is expected to start by year-end. We highlight that if approved, hGH-CTP would be the first long-acting HGH on the market. In addition, PROLOR has exclusive rights to CTP technology for all but four proteins. Merck (NYSE: MRK) developed and now sells a fertility drug using CTP modification, which we believe validates this technology. In our view, PROLOR remains still largely overlooked despite multiple 12-18 month catalysts."
For an analyst ratings summary and ratings history on PROLOR Biotech click here. For more ratings news on PROLOR Biotech click here.
Shares of PROLOR Biotech closed at $4.69 yesterday.
Oppenheimer initiates coverage on PROLOR Biotech (NYSE: PBTH) with a Outperform. PT $7.00.
Analyst, Boris Peaker, said, "PROLOR is a biopharmaceutical company developing proprietary long-acting versions of already approved therapeutics. PROLOR's leading asset is hGH-CTP, a long-acting version of human growth hormone (HGH). A Phase III trial of hGH-CTP in adults is expected to start by year-end. We highlight that if approved, hGH-CTP would be the first long-acting HGH on the market. In addition, PROLOR has exclusive rights to CTP technology for all but four proteins. Merck (NYSE: MRK) developed and now sells a fertility drug using CTP modification, which we believe validates this technology. In our view, PROLOR remains still largely overlooked despite multiple 12-18 month catalysts."
For an analyst ratings summary and ratings history on PROLOR Biotech click here. For more ratings news on PROLOR Biotech click here.
Shares of PROLOR Biotech closed at $4.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lake Street Starts RF Industries Ltd. (RFIL) at Buy
- Canaccord Starts Galiano Gold (GAU:CN) at Buy
- Benchmark Starts Allegro MicroSystems (ALGM) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
